EICHOR
● Active Not Recruiting
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
Condition: Chronic Lymphoid Leukemia · Sponsor: German CLL Study Group
About this study
The aim of this study is to compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax by measuring progression-free survival (PFS) in patients with previously untreated CLL.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (181)
| LKH-Universtitätsklinikum Graz | Graz, Austria | — |
| Landeskrankenhaus - Universitätskliniken Innsbruck | Innsbruck, Austria | — |
| Medizinische Universität Wien | Vienna, Austria | — |
| Hanusch Krankenhaus | Vienna, Austria | — |
| Wiener Gesundheitsverbund Klinik Ottakring | Vienna, Austria | — |
| Algemeen Ziekenhuis St. Jan | Bruges, Belgium | — |
| Universitair Ziekenhuis Leuven | Leuven, Belgium | — |
| Algemeen Ziekenhuis Delta | Roeselare, Belgium | — |
| Aalborg Universitetshospital | Aalborg, Denmark | — |
| Aarhus Universitetshospital | Aarhus, Denmark | — |
| Rigshospitalet | Copenhagen, Denmark | — |
| Sydvestjysk Sygehus Esbjerg | Esbjerg, Denmark | — |
+ 169 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04608318